偏好导向的生活质量监测及其与临床登记数据的关联:肺癌患者随机临床试验的研究方案(LePaLuMo研究)
该研究是一项在德国巴伐利亚两个地区开展的两臂随机、前瞻性、实用性、多中心临床试验,纳入原发性肺癌患者,干预组使用电子化患者和医生导向的生活质量监测系统并连接巴伐利亚癌症登记处临床数据,对照组也测量生活质量但医患均无法获取结果。主要终点为入组后6个月时需生活质量治疗(生活质量剖面任一维度<50分)的患者比例,研究者预期干预组低于对照组。
要点
- 干预组生活质量监测结果实时反馈给患者和医生,并建立多专业医疗提供者网络治疗生活质量缺陷。
- 对照组生活质量也测量,但患者和治疗医生均无法获取结果。
- 主要终点为入组后6个月时需生活质量治疗(任一维度<50分)的患者比例。
核心结论
- 研究者预期入组后6个月时,需生活质量治疗(生活质量剖面至少一个维度<50分)的患者比例在干预组低于对照组。
- 这是首个基于患者和医生导向偏好研究生活质量监测系统有效性的研究,通过纳入住院和门诊照护及不同研究地区具有高度可推广性。
研究设计与样本
- 两臂随机、前瞻性、实用性、多中心临床试验,设一个干预组和一个对照组,在德国巴伐利亚两个地区开展。
- 研究对象为原发性肺癌患者,使用EORTC QLQ-C30和QLQ-LC29问卷在入组时及随访1、2、3、4、5、6个月评估生活质量。
- 每位患者的生活质量数据与巴伐利亚癌症登记处的临床数据关联用于数据分析。
- 干预组生活质量监测结果自动生成包含8个维度的生活质量剖面,量表范围0-100分,需生活质量治疗的界值为<50分。
- 干预组建立多专业医疗提供者网络以治疗生活质量缺陷;对照组也测量生活质量,但患者和治疗医生均无法获取结果。
主要发现
- 原文为研究方案,未报告研究结果。
关键数值与推荐
- 生活质量剖面包含8个维度,量表范围0-100分,需生活质量治疗的界值为<50分(至少一个维度)。
- 主要终点为入组后6个月时需生活质量治疗(<50分)的患者比例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In routine oncological care, the implementation of disease-related quality of life (QoL) is still an open matter. In a complex intervention, a QoL monitoring system including tailored therapeutic options has been designed, implemented, and its effectiveness has been demonstrated in two randomised trials in patients with breast and colorectal cancer. The next step is to extend the usability of the QoL monitoring system for patients with other cancer diagnoses and in other regions. Necessary adaptations include an electronic measurement of QoL and consideration of patient and physician preferences. The present randomised trial investigates the effectiveness of this adapted QoL monitoring system in patients with lung cancer in two regions in Bavaria, Germany. METHODS: In this 2-arm randomised, prospective, pragmatic, multicentre clinical trial with one intervention and one control group, QoL of primary lung cancer patients is assessed with an electronic patient- and physician-oriented QoL monitoring system using the EORTC QLQ-C30 and QLQ-LC29 questionnaires at study entry and at 1, 2, 3, 4, 5, and 6 months during follow-up care. The QoL data of each patient are linked with clinical data from the Bavarian Cancer Registry for the purpose of data analysis. In the intervention group, the results of QoL monitoring are automatically transferred to a QoL profile including 8 dimensions on scales of 0-100 (cut-off "need for QoL therapy" < 50 points). QoL results are obtained in real-time by patients and their treating physicians. To treat QoL deficits, a multi-professional network of healthcare providers is established. In the control group, QoL is also measured, but neither patients nor treating physicians have access to the results. The investigators expect that the proportion of patients in both groups with a need for QoL therapy (< 50 points in at least one dimension of the QoL profile) will be lower in the intervention group than in the control group at the primary endpoint 6 months after study entry. DISCUSSION: This is the first study investigating the effectiveness of a QoL monitoring system based on patient- and physician-oriented preferences with a high degree of generalisability by including inpatient and outpatient care as well as different study regions. TRIAL REGISTRATION: ClinicalTrials.gov NCT06252233. Registered on February 2024.
引用
- Lindberg-Scharf P, Emmert M, Koller M, et al. Preference-oriented quality of life monitoring and linkage with clinical registry data: study protocol of a randomised clinical trial in patients with lung cancer (LePaLuMo Study). Trials. 2025. PMID: 40958112. doi:10.1186/s13063-025-09102-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。